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Bovine spongiform encephalopathy (BSE) is the only known 
zoonotic prion that causes variant Creutzfeldt-Jakob disease 
(vCJD) in humans. The major risk determinant for this disease 
is the polymorphic codon 129 of the human prion protein (Hu-
PrP), where either methionine (Met129) or valine (Val129) can 
be encoded. To date, all clinical and neuropathologically con-
firmed vCJD cases have been Met129 homozygous, with the 
exception of 1 recently reported Met/Val heterozygous case. 
Here, we found that transgenic mice homozygous for Val129 
Hu-PrP show severely restricted propagation of the BSE 
prion strain, but this constraint can be partially overcome by 
adaptation of the BSE agent to the Met129 Hu-PrP. In addition, 
the transmission of vCJD to transgenic mice homozygous for 
Val129 Hu-PrP resulted in a prion with distinct strain features. 
These observations may indicate increased risk for vCJD 
secondary transmission in Val129 Hu-PrP–positive humans 
with the emergence of new strain features.
The presence of variant Creutzfeldt-Jakob disease (vCJD) is considered by strong epidemiologic, pathologic, and 
molecular evidence to be a likely consequence of human 
dietary exposure to the bovine spongiform encephalopathy 
(BSE) agent (1–3). Secondary vCJD infection has occurred 
through iatrogenic routes such as blood transfusion (4–7). 
The pathogenesis of these fatal transmissible spongiform 
encephalopathies (TSEs), called prion diseases, is associ-
ated with the accumulation of the abnormal isoform (PrPSc) 
of prion protein (PrP), which is converted from the normal 
cellular isoform (PrPC) (8). This conversion process involves 
a posttranslational conformational change of PrPC and PrPSc 
that can be distinguished biochemically from PrPC by its par-
tial resistance to proteolysis and detergent insolubility (9,10).
The neuropathological features of vCJD are charac-
terized by the presence of abundant florid PrP plaques and 
the propagation of type 4 disease-related PrPSc in the brain 
(1,11). Differences in the level of glycosylation, as well as in 
the size of protease-digested PrPSc, are widely used as surro-
gates of prion strain typing; 2 main classifications are recog-
nized in the prion field (1,12). According to 1 of these clas-
sifications (1,13), type 4 PrPSc is characterized by a fragment 
size and glycoform ratio similar to that seen in BSE and BSE 
transmitted to several other species, with a predominance of 
the diglycosylated PrP glycoform (1,13–15).
Polymorphism at codon 129 of the human PrP gene 
(PRNP), where methionine (Met) or valine (Val) can be en-
coded, strongly affects susceptibility to human prion diseases 
(16–20). vCJD has only been neuropathologically confirmed 
in persons homozygous for Met at residue 129 of human PrP 
(21), with 1 exception of heterozygosity (Met/Val) at this co-
don (22). In addition, asymptomatic peripheral involvement 
in vCJD infection has been reported in 2 Met/Val
129
-positive 
persons (5,7). Retrospective studies of the prevalence of sub-
clinical vCJD infection using appendectomy and tonsillec-
tomy specimens in the United Kingdom described 6 appen-
dixes that were positive for disease-associated prion protein 
in Val/Val
129
 persons (23–25). All of these human studies, in 
addition to the extremely prolonged and variable incubation 
periods seen in prion transmission experiments when cross-
ing a species barrier, suggest that persons encoding any of 
the 3 human PrP codon 129 genotypes may be susceptible to 
vCJD, including secondary vCJD transmitted through blood 
transfusion, blood products, tissue and organ transplantation, 
and other iatrogenic routes.
Because only 1 definite case of heterozygous Met/
Val
129
 vCJD and no homozygous Val
129
 cases have been 
described, it is unknown whether the clinicopathologic 
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characteristics and biochemical properties of vCJD would 
appear in persons with these codon 129 genotypes. To gain 
insights into that question, vCJD/BSE transmission stud-
ies in which either humanized overexpressing or knock-in 
transgenic mice were used have been performed (2,26–30). 
However, some discrepancies in the transmission efficien-
cy of vCJD to humanized knock-in transgenic mice can be 
found, depending on the origin of the mice and on the vCJD 
isolate (29,30). Previous studies in humanized overexpress-
ing transgenic mice revealed that the 3 human PrP codon 
129 genotypes can be infected with vCJD but show sig-
nificant differences depending on the genotype. Moreover, 
mice with the Val/Val
129
 genotype were more susceptible to 
vCJD infection than expected but lack the neuropathologi-
cal characteristics observed with Met/Met
129
 (2,26–28).
In this study, we evaluated the zoonotic potential of BSE 
and BSE adapted to different species by using transgenic mice 
overexpressing similar levels of human PrPC carrying Met/
Met, Met/Val, or Val/Val at position 129 of human PrP. Fur-
thermore, we used these models to re-evaluate the potential 
for human-to-human spread of vCJD, as well as the differen-
tial susceptibility and characteristics of the transmitted disease 
across the different PRNP codon 129 genotypes in humans.
Materials and Methods
Ethics Statement
We carried out animal experiments in strict accordance 
with the recommendations in the guidelines of the Code 
for Methods and Welfare Considerations in Behavioral 
Research with Animals (Directive 86/609EC and 2010/63/
EU), and all efforts were made to minimize suffering. Ex-
periments were approved by the Committee on the Ethics 
of Animal Experiments of the Instituto Nacional de In-
vestigación y Tecnología Agraria y Alimentaria (Madrid, 
Spain; permit nos. CEEA2012/024 and CEEA2009/004).
TSE Isolates
We used 11 isolates from different sources in this study 
(Table 1 [31–39]). For mouse inoculation, we prepared all 
isolates from brain tissues as 10% weight/volume (wt/vol) 
homogenates in 5% glucose. We performed second passages 
by inoculating transgenic mice with 10% (wt/vol) homog-
enates in 5% glucose of brains selected from passage 1.
Mouse Transmission Studies
We inoculated all isolates in 3 different transgenic mouse 
models: 1) HuPrP-Tg340-Met
129
 (TgMet
129
) mouse line ex-
pressing human Met
129
-PrPC variant (31); 2) HuPrP-Tg361-
Val
129
 (TgVal
129
) mouse line expressing human Val
129
-PrPC 
variant (40); and 3) HuPrP-Tg351-Met/Val
129
 (TgMet/
Val
129
) transgenic mouse line obtained by mating TgMet
129
 
and TgVal
129
 mice (40). All of these transgenic lines show 
similar brain expression levels of PrPC (around 4-fold the 
level of expression in the human brain) on a mouse PrP 
null background. We performed additional inoculations 
in HuPrP-Tg362-Val
129
, a transgenic mouse line express-
ing 8-fold the level of PrPC expression in human brain 
(TgVal
129
 [8×]) (41). We performed subsequent bioassays 
for the detection of low-level propagation of infectious 
BSE and BSE-derived prions in BoPrP-Tg110 mice, which 
are highly susceptible to vCJD prions (42,43), probably 
caused by the trace-back phenomenon (30).
We anesthetized individually identified mice, 6–7 
weeks of age, with isoflurane and inoculated them with a 
2-mg equivalent of brain homogenate in the right parietal 
lobe by using a 25-gauge disposable hypodermic needle. 
We observed mice daily and assessed neurologic status 2 
times per week. When progression of a TSE disease was 
evident or at the established experimental endpoint (700 
days postinoculation [dpi]), we euthanized the animal 
for ethical reasons and performed necropsy, excising 
the brain. We then fixed part of the brain by immersion 
 
Table 1. Description of prion isolates used in analysis of BSE and CJD* 
Isolate Sample codification Description (reference) Supplier† 
Hu-sCJD MM1 BC 1011 sCJD PrP-Met129 type 1 human natural case BHUFA 
Hu-sCJD VV2 BC 1452 sCJD PrP-Val129 type 2 human natural case BHUFA 
Hu-TSE negative 
 
TSE free human brain NIBSC 
Ca-BSE0 Fr (139) BSE naturally infected cow (31,32) INRA 
Ca-BSE2 UK (PG1199/00) BSE naturally infected cow (33,34) VLA 
Ca-BSE0/TgPo Ca-BSE0/Tg001 BSE transmitted experimentally to porcine transgenic mice (32) CISA 
Ca-BSE0/Sh(ARQ) Fr (ARQ0) Pool of brains from terminally ill ARQ/ARQ sheep inoculated with 
Ca-BSE (31,32) 
INRA 
Ca-BSE/Go gBSE-P12 Pool of brains from 3 terminally ill wild type goats inoculated with a 
mixture of 4 cattle-BSE field cases (35–37) 
Roslin 
Go-BSE Fr (CH636) Goat BSE case (38) AFSSA 
Hu-vCJD1 UK (NHBY/0014) vCJD PrP-Met129 human infected case (39) NIBSC 
Hu-vCJD2 BC 1458 vCJD PrP-Met129 human infected case BHUFA 
*BSE, bovine spongiform encephalopathy; Ca, cattle; CJD, Creutzfeldt-Jakob disease; Go, goat; Hu, human; Met129, methionine; PrP, prion protein; sCJD, 
sporadic CJD; TSE, transmissible spongiform encephalopathy; Val129, valine; vCJD, variant CJD. 
†AFSSA, Agence Française de Sécurité Sanitaire des Aliments National TSE Reference Laboratory, Lyon, France; BHUFA, Biobanco Hospital 
Universitario Fundación Alcorcón, Madrid, Spain; CISA, Centro de Investigación en Sanidad Animal, Madrid, Spain; INRA, French National Institute for 
Agricultural Research, Nouzilly, France; NIBSC, National Institute for Biologic Standards and Control Creutzfeld-Jakob Disease Resource Centre, South 
Mimms, Potters Bar, United Kingdom; Roslin, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, 
Midlothian, United Kingdom; VLA, Veterinary Laboratory Agency, New Haw. Addlestone, Surrey, United Kingdom.  
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in neutral-buffered 10% formalin (4% 2-formaldehyde) 
and used the tissue for quantifying spongiform degen-
eration by histopathology. We froze the remaining tissue 
at –20°C and used it to determine the presence of dis-
ease-associated proteinase K (PK)–resistant PrP (PrPres) 
by Western blot. 
In all cases, we calculated mouse survival time and 
disease attack rate for each isolate. We expressed surviv-
al times as mean ±SD of the dpi for all mice positive for 
PrPres. We defined the attack rate as the proportion of all in-
oculated mice whose samples tested positive for PrPres. We 
used brain homogenates from PrPres-positive mice, where 
available, for further passaging. When all mice were scored 
negative for PrPres on primary passage, we used PrPres-nega-
tive brain homogenates for second passage.
Western Blot
We homogenized frozen brain tissues (175 ± 20 mg) in 
5% glucose in distilled water in grinding tubes (Bio-Rad, 
Hercules, CA, USA) adjusted to 10% (wt/vol) by using a 
TeSeE Precess 48TM homogenizer (Bio-Rad), according 
to the manufacturer’s instructions. We determined pres-
ence of PrPres in transgenic mouse brains by Western blot, 
using the reagents of the ELISA commercial test TeSeE 
(Bio-Rad). Based on a previously described protocol (31), 
we treated 10–100 µL of 10% wt/vol brain homogenates 
with proteinase K; the resulting samples were loaded in 
12% Bis-Tris Gel (Criterion XT; Bio-Rad). We transferred 
proteins electrophoretically onto PVDF membranes (Mil-
lipore, Billerica, MA, USA), which were blocked overnight 
with 2% BSA blocking buffer (Sigma-Aldrich, St. Louis, 
MO, USA). For immunoblotting, we incubated with Sha 
31 (44) monoclonal antibody (mAb) at a concentration of 
1 µg/mL to identify the 145-WEDRYYRE-152 epitope of 
the human PrPC sequence. To detect immunocomplexes, 
we incubated the membranes for 1 h with horseradish per-
oxidase conjugated anti-mouse IgG (GE Healthcare Amer-
sham Biosciences, Little Chalfont, UK). Immunoblots were 
developed with enhanced chemiluminiscence ECL Select 
(GE Healthcare Amersham Biosciences). Images were cap-
tured using the ChemiDoc WRS+ System (Bio-Rad) and 
processed using Image Lab 5.2.1 software (Bio-Rad).
Histopathological Analysis
We performed procedures for the histopathological analy-
sis of mouse brains as previously described (45). We im-
mediately fixed mouse brain samples in neutral-buffered 
10% formalin (4% 2-formaldehyde) during necropsy and 
embedded the tissues in paraffin later. After deparaffiniza-
tion, we stained 2 μm–thick tissue slices with hematoxylin 
and eosin and established lesion profiles by using published 
standard methods (46). We conducted paraffin-embedded 
tissue (PET) blots as previously described (47).
Results
BSE Resistance in TgVal129 Mice 
To evaluate the relative susceptibility of the 3 human PRNP 
codon 129 genotypes to BSE, we performed serial transmis-
sion studies in 3 transgenic mouse lines expressing human 
PrP. These mouse lines were homozygous for Met (TgMet
129
) 
or Val (TgVal
129
) at codon 129 of human PrP or were their 
F1 cross (TgMet/Val
129
). These mouse models expressed 
similar human PrP levels, ≈4-fold more than that seen in un-
infected human brain tissue (40). We observed no clinical 
signs of prion disease or PrPres accumulation in control mice 
inoculated with TSE-free control brain homogenate. The 3 
human transgenic mouse models were readily infected when 
inoculated with sporadic CJD (sCJD) (Table 2). The 2 sCJD 
cases used as inocula in this study were classified as Met
129
 
type 1 (Hu-sCJD MM1) and Val
129
 type 2 (Hu-sCJD VV2) 
(12) on the basis of the patient´s PRNP genotype at codon 
129 and the PrPres Western blot profiles of these samples.
We inoculated the 3 mouse models intracerebrally with a 
panel of BSE isolates from different species (cattle, pig, sheep, 
and goat; Table 2). As previously described in TgMet
129
 mice 
(31), we found a higher transmission efficiency adjudged by 
comparatively higher attack rates for BSE isolates previously 
passaged in other species than for cattle BSE, suggesting a 
strong transmission barrier to cattle BSE in these mice.
At completion of the first and second passages, none of the 
TgVal
129
 mice challenged with the different BSE isolates de-
veloped clinical disease, and no PrPres accumulation was found 
in their brains (Table 2). Because of intercurrent illnesses, the 
group of TgVal
129
 mice challenged with Ca-BSE
2
 was con-
siderably reduced in size; however, the absence of transmis-
sion to TgVal
129
 mice challenged with a second BSE inocula, 
Ca-BSE
0
, reinforces this negative result. In addition, results 
of subsequent passage of brain homogenates from these mice 
to BoPrP-Tg110 mice were negative, ruling out the presence 
of subclinical infection, with the exception of TgVal
129
 mice 
inoculated with Go-BSE. For this isolate, 3 of 6 BoPrP-Tg110 
mouse brains showed detectable PrPres and had a long incu-
bation time of 427 ± 38 dpi, suggesting very low infectivity 
(online Technical Appendix Table 1, https://wwwnc.cdc.gov/
eid/article/23/9/16-1948-Techapp.pdf).
To confirm that the lack of susceptibility of TgVal
129
 
mice to cattle BSE and to BSE previously adapted in differ-
ent species was not caused by inadequate PrP substrate, we 
used the TgVal
129
 (8×) mouse line (41). However, even un-
der these high human PrP expression level conditions, none 
of the inoculated TgVal
129
 (8×) mice showed any evidence 
of infection after challenge with the different BSE isolates 
(online Technical Appendix Table 2). This result indicates 
that even an increase in the TgVal
129
 PrP expression level is 
not enough to allow transmission of BSE prions, irrespective 
of the species in which BSE has been previously passaged.
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In a similar manner to that seen in the TgVal
129
 mice, 
we observed no clinical disease and no disease-associated 
PK-resistant PrP accumulation on first or second passage 
of the different BSE isolates in TgMet/Val
129
 mice. How-
ever, we did observe an exception in 1 TgMet/Val
129
 mouse 
inoculated with Go-BSE without clinical signs but with a 
positive score for brain PrPres that died at 476 dpi (Table 2). 
These findings support the interpretation that human-PrP 
Val
129
 polymorphism severely restricts propagation of the 
BSE prion strain independently of the species in which it 
had previously been adapted.
BSE Adaptation to the Human PrP Sequence
In parallel to the transmission experiments with the different 
BSE isolates, we also inoculated the 3 humanized transgen-
ic mouse models with human brain material from 2 differ-
ent cases of vCJD PrP-Met
129
 (Hu-vCJD
1
 and Hu-vCJD
2
). 
On first passage, 100% of the TgMet
129
 mice developed 
clinical disease in response to all inocula in the panel (Ta-
ble 3). However, only the inoculum Hu-vCJD
2
 previously 
passaged in TgMet/Val
129
 mice caused clinical disease in 
the same heterozygous genotype upon serial passages; the 
rest of the inocula caused only subclinical infections in this 
genotype (Table 3). 
The PrPres molecular profile (Figure 1, panel A, lanes 
2, 3, and 5; Figure 1, panel B) and the PrPres distribution 
patterns on paraffin-embedded tissue (PET) blots in the 
mouse brains (Figure 2, panels A, B, C) were similar in 
both the TgMet
129
 and TgMet/Val
129
 mice, with or with-
out clinical disease. However, we consistently observed 
a lower PrPres accumulation in TgMet/Val
129
 mice com-
pared with TgMet homozygous animals, particularly in the 
hippocampus area, probably caused by a slower conversion 
rate of PrPSc in these animals with a half dose of PrP-Met
129
.
 
Table 2. Transmission of cattle, porcine, sheep, and goat BSE isolates to mice in transgenic mouse lines TgMet129, TgMet/Val129, and 
TgVal129* 
Isolates 
Mean survival time, d ±SD (no. PrPres-positive/inoculated animals) [reference]†‡ 
TgMet129 
 
TgMet/Val129 
 
TgVal129 
First passage Second passage First passage Second passage First passage Second passage 
Hu-sCJD MM1 219 ±17 (6/6) 
[40] 
239 ±8 (6/6) [40]  243 ±14 (6/6) 
[40] 
260 ±13 (6/6) 
[40] 
 327 ±19 (6/6) 
[40] 
286 ±16 (6/6) 
[40] 
Hu-sCJD VV2 618 ±81 (6/6) 
[40] 
509 ±41 (6/6) 
[40] 
 588 ±74 (6/6) 
[40] 
594 ±86 (6/6) 
[40] 
 168 ±12 (6/6) 
[40] 
169 ±12 (6/6) 
[40] 
Hu-TSE negative >700‡ (0/6) >700‡ (0/6)  >700‡ (0/6) >700‡ (0/6)  >700‡ (0/6) >700‡ (0/6) 
Ca-BSE0 739 (1/6) (31) 633 ±32 (6/6)  >700‡ (0/6) >700‡ (0/6)  >700‡ (0/6) >700‡ (0/6) 
Ca-BSE2 491–707 (0/9) 
[31] 
572 ±37 (3/4) 
[31] 
 >700‡ (0/5) ND  >700‡ (0/3)§ >700‡ (0/3§ 
Ca-BSE/TgPo 653 ±45 (3/5) ND  ND ND  >700‡ (0/6) ND 
Ca-BSE/Sh(ARQ) 615 ±84 (4/6) 
[31] 
564 ±39 (5/5) 
[31] 
 >700b (0/6) >700‡ (0/6)  >700‡ (0/6) >700‡ (0/6) 
Ca-BSE/Go >700‡ (5/5) >700‡ (5/5)  476 (1/10) ND  >700‡ (0/5)¶ ND 
Go-BSE 683 ± 36 (6/6) 675 ± 36 (5/5)  >700‡ (0/6) ND  >700‡ (0/6) ND 
*BSE, bovine spongiform encephalopathy; Ca, cattle; CJD, Creutzfeldt-Jakob disease; Go, goat; Hu, human; Met129, methionine; ND, not done; PrPres, 
proteinase K–resistant PrP; sCJD, sporadic CJD; Val129, valine; vCJD, variant CJD.  
†Survival time is indicated for all mice that scored positive for PrPres 
‡Animals without clinical signs were euthanized at 700 dpi. 
§Three additional animals were culled before the end of the experiment because of intercurrent illnesses; all were negative for brain PrPres by using 
Western blot. 
¶Positive subclinical infection tested in Bo-Tg110 mice. 
 
 
Table 3. Intracerebral inoculation of transgenic mice that express human PrP with vCJD and with vCJD previously adapted in 
TgMet129 or TgMet/Val129 mice* 
Isolates 
Mean survival time, d ±SD (no. PrPres-positive/inoculated animals) [reference]† 
TgMet129 TgMet/Val129 TgVal129 
Hu-vCJD1 626 ±29 (6/6) [31] >700‡ (3/3)§ >700‡ (0/5) 
Hu-vCJD1TgMet129 650 ±60 (4/4) >700‡ (5/5) >700‡ (5/5) 
Hu-vCJD2 545 ±146 (5/5) >700‡ (5/5) >700‡ (0/6)# 
Hu-vCJD2TgMet129 564 ±39 (4/4) >700‡ (5/5) >700‡ (2/2)¶ 
Hu-vCJD2TgMet/Val129 601 ±32 (5/5) 651 ±17 (7/7) >700‡ (7/7) 
Ca-BSE2TgMet129 614 ±87 (6/6) >700‡ (4/4) >700‡ (3/4) 
Ca-BSE/Sh(ARQ)TgMet129 534 ±55 (5/6) >700‡ (5/6) >700‡ (5/6) 
Ca-BSE/GoTgMet129 609 ±67 (5/5) >700‡ (4/4) >700‡ (6/6) 
*BSE, bovine spongiform encephalopathy; Ca, cattle; CJD, Creutzfeldt-Jakob disease; Go, goat; Hu, human; Met129, methionine; PrP, prion protein; 
PrPres, proteinase K–resistant PrP; sCJD, sporadic CJD; Val129, valine; vCJD, variant CJD. 
†Survival time is indicated for all mice scored positive for PrPres. 
‡Animals were euthanized without clinical signs at 700 dpi. 
§Three additional animals had to be culled before the end of the experiment because of intercurrent illnesses; all were negative for brain PrPres on WB. 
¶Four additional animals had to be culled before the end of the experiment because of intercurrent illnesses; all were negative for PrPres expression on 
Western blot. 
#Positive subclinical infection tested in Bo-Tg110 mice. 
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In sharp contrast, none of the TgVal
129
 mice challenged 
with the 2 vCJD primary inocula, Hu-vCJD
1
 and Hu-vCJD
2
, 
developed clinical disease and no PrPres accumulation was 
found in their brains after Western blot (WB) analysis 
(Table 3). However, subsequent passage of brain homog-
enates from TgVal
129
 mice inoculated with Hu-vCJD
2
 (that 
remained apparently uninfected) to BoPrP-Tg110 mice 
showed evidence of subclinical infection. These subpas-
sages led to a mean incubation time of 371 ± 5 dpi and to 
propagation of PrPres that was detectable by WB in 100% 
of animals (online Technical Appendix Table 1), showing 
a biochemical pattern indistinguishable from that of cattle 
BSE infection in this mouse model.
These results suggest that the adaptation of the BSE 
agent to human PrP sequence could favor its transmission 
to the polymorphic human PrP Val
129
 genotype. In this 
context, we passaged all isolates in TgMet
129
 mice before 
subsequent inoculation in TgVal
129
 mice. Although we did 
not observe clinical prion disease, the inoculated TgVal
129
 
mice had an infection rate remarkably close to 100%, as as-
sessed by the presence of brain PrPres at the end of the ex-
periment (Table 3). We obtained similar results with the 
Hu-vCJD
2
 isolate after 1 passage in TgMet/Val
129
 mice and 
subsequent inoculation into TgVal
129
 mice (Table 3). These 
observations support the hypothesis that adaptation of BSE 
agent to the human-PrP Met
129
 amino-acid sequence pro-
motes its transmission to human PrP Val
129
–expressing hosts.
vCJD Prions in TgVal129 Mice 
Challenge of TgMet
129
 or TgMet/Val
129
 mice with vCJD 
prions resulted in faithful propagation of a typical PrPvCJD 
(also named type 4), characterized by low size fragments 
(19-kDa fragment for the aglycosyl band) and prominent 
diglycosylated species on WB (Figure 1, panel A, lanes 2, 
Figure 1. Biochemical features of the protease-resistant prion protein (PrPres) detected in the brain of TgMet129, TgMet/Val129, and 
TgVal129 mice inoculated with vCJD. A) PrP
res detected in TgMet129 (lanes 2 and 5), TgMet/Val129 (lane 3), and TgVal129 (lanes 4 and 
6) mice inoculated with vCJD brain homogenate or TgMet129-passaged vCJD prions. Similar quantities of PrP
res were loaded for 
adequate comparison and immunoblots were detected with Sha31 monoclonal antibody (mAb). The original vCJD isolate (Hu-vCJD2) 
used for mouse inoculations was also included in the blot (lanes 1 and 7). sCJD VV2 and MM1 isolates were included for biochemical 
comparative purposes (lanes 8 and 9, respectively). Molecular weight (MW) in kDa is shown. B) Glycoform analysis of PrPres from 
TgMet129, TgMet/Val129, and TgVal129 mice inoculated with vCJD brain homogenate or TgMet129-passaged vCJD prions. PrP
res was 
detected by Western blot testing using the Sha31 mAb, as for panel A. The data shown are the means of >4 measurements in >2 
different Western blots using the Image Lab (Bio-Rad, Hercules, CA, USA)  program after capture with ChemiDoc XRS+ (Bio-Rad)  
under nonsaturating conditions. Error bars indicate SD. CJD, Creutzfeldt-Jakob disease; sCJD, sporadic CJD; vCJD, variant CJD.
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3). These biochemical properties were accompanied by the 
key neuropathological hallmark of vCJD, the presence of 
abundant florid PrP plaques determined by immunohisto-
chemical analysis of the brain (31) (data not shown).
In contrast, TgMet
129
-passaged vCJD-inoculated 
TgVal
129
 mice propagated a PrPSc with a WB signature 
that shared the same predominance of the diglycosylated 
glycoform seen in type 4 PrPSc but was distinguished by 
PK digestion products of greater molecular mass (Figure 
1, panel A, lanes 4, 6), which closely resemble those seen 
in human type 2 PrPSc (Figure 1, panel A, lane 8). This dif-
ferential biochemical pattern is associated with the pres-
ence of amyloid plaques restricted to the corpus callosum 
without a florid morphology. Moreover, we saw no spe-
cific vacuolar changes in the brains of these animals. PET 
blot analysis of these brains confirmed PrPSc deposition in 
corpus callosum and head of caudate nucleus in the brain 
of vCJD-inoculated TgVal
129
 mice (Figure 2, panels D, E). 
However, PrPSc deposition was quite limited in comparison 
with those observed in vCJD-inoculated TgMet
129
 (Figure 
2, panels A, B) and TgMet/Val
129
 mice (Figure 2, panel C).
These results resemble those previously described in 
a different TgVal
129
 mouse line in which neuropathologi-
cal and molecular features similar to those observed in our 
TgVal
129
 were characterized (2,27,28). To prove the same 
PrPres molecular profile identity between this previously 
characterized PrPSc (called type 5 PrPSc, vCJD→129VV 
Tg152c) and our vCJD-TgVal
129
 PrPSc, we performed a bio-
chemical characterization by WB and found no molecular 
profile differences in PrPres from the various mouse lines 
(Figure 3, lanes 6 and 7). These particular molecular mass 
and glycoform profile characteristics seem to be a hallmark 
of vCJD transmission to human-PrP Val
129
, since these 
features were also found in a different human-PrP Val
129
 
transgenic mouse line challenged with vCJD (vCJD→ 
Ki-Hu129V/V) (26) (Figure 3, lane 8). These results, 
suggesting vCJD prion infection can result in the generation 
of distinct molecular and neuropathological phenotypes 
dependent on human-PrP polymorphic residue 129, are in 
accordance with those reported previously (2,28,46).
Discussion
We report a detailed comparison of the transmission prop-
erties of BSE and vCJD prions among humanized transgen-
ic mice with different PRNP codon 129 genotypes. Because 
a high expression level of PrP in transgenic mice directly 
influences prion disease susceptibility and incubation time, 
these transgenic mice have an advantage over knock-in 
mice for evaluating these features in the different human 
PrP genotypes. In addition, the 3 mouse models used in our 
study have equivalent PrP expression levels, making them 
suitable for studying comparative susceptibilities across 
the different PRNP codon 129 genotypes.
In previous reports, we demonstrated that Met
129
 ho-
mozygous individuals might be susceptible to a sheep or 
goat BSE agent to a higher degree than to cattle BSE and 
that these agents might transmit with molecular and neu-
ropathological properties indistinguishable from those of 
vCJD (31). In this study, we wanted to extend these results 
to the other human PRNP genotypes: Met/Val
129
 and Val/
Val
129
. We gained a different perspective when several BSE 
isolates adapted to different species inoculated in TgVal
129
 
mice showed an apparent lack of transmission. In addition, 
almost all inoculated TgMet/Val
129
 mice did not transmit 
BSE; this finding supports the interpretation by Wadsworth 
et al. that human PrP Val
129
 severely restricts propagation 
of the BSE prion strain (27). 
An unexpected result of this study was the finding 
that 1 BSE isolate from a goat (Ca-BSE/Go) was clinically 
transmitted to 1 of 10 TgMet/Val
129
 mice and subclinically 
transmitted to TgVal
129
 mice. This particular isolate is char-
acterized by a high infectious titer (35) that could explain 
the potential for this inoculum to overcome the restriction 
on BSE prions to propagate in TgVal
129
 mice.
Although cattle BSE did not transmit to TgMet/Val
129
 
mice directly, adaptation of the BSE agent to human PrP 
Figure 2. Protease-resistant prion protein distribution pattern in brains of prion protein humanized transgenic mice inoculated with 
variant Creutzfeldt-Jakob disease (vCJD) on second passage. A, B) TgMet129 mice inoculated with vCJD. C) TgMet/Val129 mice 
inoculated with vCJD. D, E) TgVal129 mice inoculated with vCJD propagated in TgMet129 mice. Original magnification ×20 for all panels.
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Met
129
 sequence and subsequent inoculation of the resultant 
vCJD prions to TgMet/Val
129
 mice produced a 100% attack 
rate. However, we did not detect clinical prion disease, sup-
porting a slower rate of vCJD conversion compared with 
that among TgMet
129
 mice. This slow but potential con-
version rate in TgMet/Val
129
 mice correlates well with the 
single vCJD case of a human carrying the PrP Met/Val
129
 
genotype (22) and with the description of subclinical sec-
ondary transmissions through human vCJD–infected tis-
sues (4–7,47).
TgVal
129
 mice challenged with Hu-vCJD
2
 did not pro-
duce detectable brain PrPres and clinical signs, in spite of 
the overexpression of HuPrP-Val
129
 and the use of the more 
efficient intracerebral route of infection. However, sub-
clinical infection in these TgVal
129
 mice was demonstrated 
in BoPrP-Tg110 mice. These data suggest that PrP Val
129
 
could sustain a very slow and limited vCJD conversion rate 
that is consistent with the detection of PrPres in tonsils and 
appendixes of asymptomatic PrP Val
129
 persons (23–25). 
Previous studies of other transgenic mice expressing PrP 
Val
129
 have also shown a low transmission efficiency of 
vCJD (2,27,30).
The fluctuating subclinical transmissibility of both 
vCJD inocula in TgVal
129
 mice (negative for Hu-vCJD
1
 and 
positive for Hu-vCJD
2
) might be caused by differences in 
prion titer between inocula. This assessment was strength-
ened after the transmission of both vCJDs to TgMet
129
 
mice, in which a shorter incubation period was observed 
in animals inoculated with Hu-vCJD
2
. A certain variability 
in subclinical transmissibility and incubation time between 
different vCJD isolates is not uncommon, as has been pre-
viously reported (2,27,30), suggesting that a Val
129
 trans-
mission barrier can only be overcome with highly infec-
tious vCJD isolates.
The dramatic changes in the susceptibility of TgVal
129
 
mice (Table 3) challenged with vCJD isolates first pas-
saged in TgMet
129
 mice suggest an apparent increase in ti-
ter of both vCJD prion isolates; however, adaptation of the 
inocula to the new host mouse cannot be disregarded as be-
ing partly responsible for this increased susceptibility. We 
observed a 100% infection rate, but without clinical signs 
of prion disease. We observed similar transmission features 
when we passaged vCJD in TgMet/Val
129
 mice. In addition, 
the apparent PrPVal
129
 restricted propagation of cattle BSE 
and BSE from other species was completely abolished after 
its adaptation to human PrPMet
129
.
Although PrP overexpression and the inoculation 
route can affect transmission efficiency, our results and 
those previously reported in both overexpressing and 
knock-in transgenic mice (2,27,30) suggest that the Val
129
 
PrP variant could sustain a very slow and limited vCJD 
conversion rate, and is unable to completely prevent 
vCJD transmission. Biochemical and neuropathological 
features of vCJD transmission to TgVal
129
 mice showed 
substantial differences compared to TgMet
129
 or TgMet/
Val
129
 mice. Similar to previous reports (2,27,28,48), a 
type 5 PrPSc associated with very weak and diffuse PrP 
plaques without a florid morphology was the hallmark 
among these mice. In addition, our demonstration of pre-
viously unreported type 5 PrPSc in brain samples of vCJD-
challenged knock-in Ki-Hu129V/V mice (30) establish-
es that the evolution of type 5 PrPSc associated with the 
transmission of vCJD prions to the Val
129
 genotype is not 
Figure 3. Biochemical comparison of brain protease-resistant 
prion protein (PrPres) detected in transgenic mice expressing 
prion protein Met129 and Val129 mice and inoculated with vCJD 
brain homogenate. Similar quantities of PrPres were loaded for 
adequate comparison, and immunoblots were detected by using 
Sha31 monoclonal antibody. Lanes 4 and 6 show passages from 
this study; lane 5 shows sample codification I-10629 and lane 7 
sample codification I-11724 from the MRC Prion Unit in the United 
Kingdom (27); lane 8 shows sample codification #139-A5603 
from Tohoku University Graduate School of Medicine, Sendai, 
Japan (30). The original vCJD isolate (Hu-vCJD2) used for mouse 
inoculations in this study was also included on the blot (lanes 
3 and 9); sCJD MM1 (lane 1) and VV2 (lane 2) isolates were 
included for biochemical comparative purposes. Molecular weight 
(MW) in kDa is shown. CJD, Creutzfeldt-Jakob disease; sCJD, 
sporadic CJD; vCJD, variant CJD.
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an artifact of PrP overexpression. This finding further re-
inforces the specific biochemical features of vCJD when 
transmitted to the human-PrP Val
129
 sequence.
Extrapolation of results from prion transmission stud-
ies based on transgenic mice has to be done with caution, 
especially when human susceptibility to prions is analyzed. 
However, our results clearly indicate that PrPVal
129
 indi-
viduals are highly resistant to transmission of cattle BSE 
or BSE passaged in other species. Also, PrPVal
129
 individu-
als might be susceptible to infection with human-passaged 
BSE (vCJD) prions, and the propagated agents might 
transmit with molecular and neuropathological properties 
distinguishable from those of type 4 PrPres. Although the 
resultant type 5 PrPSc shares the same fragment sizes as 
those of type 2 PrPSc, the 2 PrPSc types can be distinguished 
by the predominance of the diglycosylated glycoform as-
sociated with type 5 PrPSc. Overall, our results indicate that 
human Val
129
-PrP polymorphic variant is a strong molecu-
lar protector against BSE zoonotic transmission but fails 
to prevent human-to-human vCJD transmission. Because 
potential late-onset vCJD cases could appear in the popula-
tion (49,50) these findings underline the need for continued 
investigation of all forms of human prion disease.
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